Nexalin Technology shares rise 10.19% premarket after promising results in Gambling Disorder treatment trial.

Nexalin Technology surged 10.19% in premarket trading following the release of promising clinical results for its 15 mA neurostimulation device in treating gambling disorder with comorbid alcohol use, announced 16 minutes prior. The data, published by GlobeNewswire, highlight the device’s potential to address a significant unmet medical need, bolstering investor confidence ahead of the stock’s opening. While other recent developments, such as regulatory approvals in Israel and Alzheimer’s-related updates, occurred weeks earlier, the immediate premarket rally aligns with the latest clinical trial outcome, underscoring market optimism about the device’s therapeutic applications and commercial prospects.